摘要
目的:考察在大鼠体内联合应用吉非罗齐(吉非贝齐)和米格列奈后,米格列奈的药动学行为变化,为2种药物的临床应用提供依据。方法:20只SD大鼠随机分成2组,每组10只。联合用药组和对照组分别连续7d灌服吉非罗齐或0.5%CMC-Na混悬液,第8天早晨同时灌服米格列奈溶液,给药后于不同时刻采血。采用HPLC-MS-MS法测定米格列奈的血药浓度。结果:经统计分析,联合或单独给药后,米格列奈在大鼠体内的tmax、Cmax和Vd差异无显著性(P>0.05),但联合用药组的AUC0-10和AUC0-∞分别为对照组的1.5倍和2.3倍,t1/2为对照组的3.0倍,CL/F为对照组的0.42倍,MRT为对照组的5.7倍,Ke为对照的0.18倍。上述参数经检验差异均存在显著性(P<0.05)。结论:吉非罗齐与米格列奈联用后,可加大米格列奈的吸收程度,减慢消除速度。
To explore on the influence of gemfibrozil on the pharmaeokinetie mitiglinide in rats when the twodrugs were administrated in combination; and to afford experimental basis for the two drugs used in combination in clinic. METHODS 20 SD rats were divided into two groups （combination group and control group）, randomly. The rats in combination group were administrated of gemfibrozil for 7 days continuously, while the rats in control group were administrated of 0. 5% CMC-Na. In the morning of 8th day, the rats in both two groups were administrated of mitiglinide. The plasma concentrations of mitiglinide which were used to estimate pharmacokinetic parameters were determined by HPLC-MS/MS. RESULTS No differences were observed of t C and Vd in both two groups （P〉0. 05）. But the AUC0-10, AUG0-∞, t1/2, CL/F, MRT and Ke of combination group was 1.5,2.3, 3.0,0. 42,5.7 and 0. 18 times to control group, respectively（P〈0.05）. CONCLUSION The absorption of mitiglinide was strengthened and the elimination was decreased when it was combined administrated in combination gemfibrozil.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2010年第22期1894-1897,共4页
Chinese Journal of Hospital Pharmacy
